<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32089764</PMID><DateCompleted><Year>2020</Year><Month>09</Month><Day>17</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>04</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1942-0994</ISSN><JournalIssue CitedMedium="Internet"><Volume>2020</Volume><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>Oxidative medicine and cellular longevity</Title><ISOAbbreviation>Oxid Med Cell Longev</ISOAbbreviation></Journal><ArticleTitle><i>Bidens pilosa</i> Extract Administered after Symptom Onset Attenuates Glial Activation, Improves Motor Performance, and Prolongs Survival in a Mouse Model of Amyotrophic Lateral Sclerosis.</ArticleTitle><Pagination><StartPage>1020673</StartPage><MedlinePgn>1020673</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1020673</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1155/2020/1020673</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a late-onset neurodegenerative disorder characterized by progressive paralysis resulting from the death of upper and lower motor neurons. There is currently no effective pharmacological treatment for ALS, and the two approved drugs riluzole and edaravone have limited effects on the symptoms and only slightly prolong the life of patients. Therefore, the development of effective therapeutic strategies is of paramount importance. In this study, we investigated whether Miyako Island <i>Bidens pilosa</i> (MBP) can alleviate the neurological deterioration observed in a superoxide dismutase-1 G93A mutant transgenic mouse (G93A mouse) model of ALS. We orally administered 2&#x2009;g/kg/day of MBP to G93A mice at the onset of symptoms of neurodegeneration (15 weeks old) until death. Treatment with MBP markedly prolonged the life of ALS model mice by approximately 20 days compared to that of vehicle-treated ALS model mice and significantly improved motor performance. MBP treatment prevented the reduction in SMI32 expression, a neuronal marker protein, and attenuated astrocyte (detected by GFAP) and microglia (detected by Iba-1) activation in the spinal cord of G93A mice at the end stage of the disease (18 weeks old). Our results indicate that MBP administered after the onset of ALS symptoms suppressed the inflammatory activation of microglia and astrocytes in the spinal cord of the G93A ALS model mice, thus improving their quality of life. MBP may be a potential therapeutic agent for ALS.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 Yasuhiro Kosuge et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kosuge</LastName><ForeName>Yasuhiro</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-7513-5132</Identifier><AffiliationInfo><Affiliation>Laboratory of Pharmacology, School of Pharmacy, Nihon University, 7-7-1 Narashinodai, Funabashi-shi, Chiba 274-8555, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaneko</LastName><ForeName>Erina</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Laboratory of Pharmacology, School of Pharmacy, Nihon University, 7-7-1 Narashinodai, Funabashi-shi, Chiba 274-8555, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nango</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-8271-9937</Identifier><AffiliationInfo><Affiliation>Laboratory of Pharmacology, School of Pharmacy, Nihon University, 7-7-1 Narashinodai, Funabashi-shi, Chiba 274-8555, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyagishi</LastName><ForeName>Hiroko</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-3909-867X</Identifier><AffiliationInfo><Affiliation>Laboratory of Pharmacology, School of Pharmacy, Nihon University, 7-7-1 Narashinodai, Funabashi-shi, Chiba 274-8555, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishige</LastName><ForeName>Kumiko</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Laboratory of Pharmacology, School of Pharmacy, Nihon University, 7-7-1 Narashinodai, Funabashi-shi, Chiba 274-8555, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ito</LastName><ForeName>Yoshihisa</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-3385-5705</Identifier><AffiliationInfo><Affiliation>Laboratory of Pharmacology, School of Pharmacy, Nihon University, 7-7-1 Narashinodai, Funabashi-shi, Chiba 274-8555, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>01</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Oxid Med Cell Longev</MedlineTA><NlmUniqueID>101479826</NlmUniqueID><ISSNLinking>1942-0994</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004365">Drugs, Chinese Herbal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C442780">plant extract, Bidens pilosa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D031176" MajorTopicYN="N">Bidens</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004365" MajorTopicYN="N">Drugs, Chinese Herbal</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare that they have no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>10</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>12</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>1</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32089764</ArticleId><ArticleId IdType="pmc">PMC7008255</ArticleId><ArticleId IdType="doi">10.1155/2020/1020673</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rosen D. R., Siddique T., Patterson D., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362(6415):59&#x2013;62. doi: 10.1038/362059a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/362059a0</ArticleId><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney M. E., Pu H., Chiu A. Y., et al. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science. 1994;264(5166):1772&#x2013;1775. doi: 10.1126/science.8209258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8209258</ArticleId><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferraiuolo L., Kirby J., Grierson A. J., Sendtner M., Shaw P. J. Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. Nature Reviews Neurology. 2011;7(11):616&#x2013;630. doi: 10.1038/nrneurol.2011.152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2011.152</ArticleId><ArticleId IdType="pubmed">22051914</ArticleId></ArticleIdList></Reference><Reference><Citation>Dachet F., Liu J., Ravits J., Song F. Predicting disease specific spinal motor neurons and glia in sporadic ALS. Neurobiology of Disease. 2019;130, article 104523 doi: 10.1016/j.nbd.2019.104523.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2019.104523</ArticleId><ArticleId IdType="pubmed">31276795</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang L. L., Zhu B., Zhao Y., et al. Membralin deficiency dysregulates astrocytic glutamate homeostasis leading to ALS-like impairment. The Journal of Clinical Investigation. 2019;129(8):3103&#x2013;3120. doi: 10.1172/JCI127695.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI127695</ArticleId><ArticleId IdType="pmc">PMC6668683</ArticleId><ArticleId IdType="pubmed">31112137</ArticleId></ArticleIdList></Reference><Reference><Citation>Geloso M. C., Corvino V., Marchese E., Serrano A., Michetti F., D&#x2019;Ambrosi N. The dual role of microglia in ALS: mechanisms and therapeutic approaches. Frontiers in Aging Neuroscience. 2017;9:p. 242. doi: 10.3389/fnagi.2017.00242.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2017.00242</ArticleId><ArticleId IdType="pmc">PMC5524666</ArticleId><ArticleId IdType="pubmed">28790913</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J., Hyeon S. J., Im H., Ryu H., Kim Y., Ryu H. Astrocytes and microglia as non-cell autonomous players in the pathogenesis of ALS. Experimental Neurobiology. 2016;25(5):233&#x2013;240. doi: 10.5607/en.2016.25.5.233.</Citation><ArticleIdList><ArticleId IdType="doi">10.5607/en.2016.25.5.233</ArticleId><ArticleId IdType="pmc">PMC5081469</ArticleId><ArticleId IdType="pubmed">27790057</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensimon G., Lacomblez L., Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/riluzole study group. The New England Journal of Medicine. 1994;330(9):585&#x2013;591. doi: 10.1056/NEJM199403033300901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199403033300901</ArticleId><ArticleId IdType="pubmed">8302340</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawada H. Clinical efficacy of edaravone for the treatment of amyotrophic lateral sclerosis. Expert Opinion on Pharmacotherapy. 2017;18(7):735&#x2013;738. doi: 10.1080/14656566.2017.1319937.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14656566.2017.1319937</ArticleId><ArticleId IdType="pubmed">28406335</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartolome A. P., Villasenor I. M., Yang W. C. Bidens pilosa L. (Asteraceae): botanical properties, traditional uses, phytochemistry, and pharmacology. Evidence-Based Complementary and Alternative Medicine. 2013;2013:51. doi: 10.1155/2013/340215.340215</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/340215</ArticleId><ArticleId IdType="pmc">PMC3712223</ArticleId><ArticleId IdType="pubmed">23935661</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsumoto T., Horiuchi M., Kamata K., Seyama Y. Effects of Bidens pilosa L. var. radiata SCHERFF treated with enzyme on histamine-induced contraction of Guinea pig ileum and on histamine release from mast cells. Journal of Smooth Muscle Research. 2009;45(2-3):75&#x2013;86. doi: 10.1540/jsmr.45.75.</Citation><ArticleIdList><ArticleId IdType="doi">10.1540/jsmr.45.75</ArticleId><ArticleId IdType="pubmed">19602852</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyuki S., Eiji U., Takanori K., Makio S., Daisuke T., Genjiro K. Studies on the antioxidant active constituents of the dried powder from Bidens polosa L. var. radiata SCH. Natural Medicines. 2003;57(3):100&#x2013;104.</Citation></Reference><Reference><Citation>Nakama S., Tamaki K., Ishikawa C., Tadano M., Mori N. Efficacy of Bidens pilosa extract against herpes simplex virus infection in vitro and in vivo. Evidence-Based Complementary and Alternative Medicine. 2012;2012:10. doi: 10.1155/2012/413453.413453</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/413453</ArticleId><ArticleId IdType="pmc">PMC3303703</ArticleId><ArticleId IdType="pubmed">22474501</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakama S., Ishikawa C., Nakachi S., Mori N. Anti-adult T-cell leukemia effects of Bidens pilosa. International Journal of Oncology. 2011;38(4):1163&#x2013;1173. doi: 10.3892/ijo.2011.939.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ijo.2011.939</ArticleId><ArticleId IdType="pubmed">21318218</ArticleId></ArticleIdList></Reference><Reference><Citation>Horiuchi M., Seyama Y. Antiinflammatory and antiallergic activity of Bidens pilosa L. var. radiata SCHERFF. Journal of Health Science. 2006;52(6):711&#x2013;717. doi: 10.1248/jhs.52.711.</Citation><ArticleIdList><ArticleId IdType="doi">10.1248/jhs.52.711</ArticleId></ArticleIdList></Reference><Reference><Citation>Horiuchi M., Wachi H., Seyama Y. Effects of Bidens pilosa L. var. radiata Scherff on experimental gastric lesion. Journal of Natural Medicines. 2010;64(4):430&#x2013;435. doi: 10.1007/s11418-010-0426-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11418-010-0426-5</ArticleId><ArticleId IdType="pubmed">20526746</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyagishi H., Kosuge Y., Ishige K., Ito Y. Expression of microsomal prostaglandin E synthase-1 in the spinal cord in a transgenic mouse model of amyotrophic lateral sclerosis. Journal of Pharmacological Sciences. 2012;118(2):225&#x2013;236. doi: 10.1254/jphs.11221fp.</Citation><ArticleIdList><ArticleId IdType="doi">10.1254/jphs.11221fp</ArticleId><ArticleId IdType="pubmed">22302024</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosuge Y., Koen Y., Ishige K., et al. S-Allyl-L-cysteine selectively protects cultured rat hippocampal neurons from amyloid beta-protein- and tunicamycin-induced neuronal death. Neuroscience. 2003;122(4):885&#x2013;895. doi: 10.1016/j.neuroscience.2003.08.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2003.08.026</ArticleId><ArticleId IdType="pubmed">14643758</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosuge Y., Miyagishi H., Yoneoka Y., et al. Pathophysiological role of prostaglandin E2-induced up-regulation of the EP2 receptor in motor neuron-like NSC-34 cells and lumbar motor neurons in ALS model mice. Neurochemistry International. 2018;119:132&#x2013;139. doi: 10.1016/j.neuint.2017.06.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuint.2017.06.013</ArticleId><ArticleId IdType="pubmed">28687401</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyagishi H., Kosuge Y., Takano A., et al. Increased expression of 15-hydroxyprostaglandin dehydrogenase in spinal astrocytes during disease progression in a model of amyotrophic lateral sclerosis. Cellular and Molecular Neurobiology. 2017;37(3):445&#x2013;452. doi: 10.1007/s10571-016-0377-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10571-016-0377-9</ArticleId><ArticleId IdType="pubmed">27140190</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosuge Y., Miyagishi H., Shinomiya T., et al. Characterization of motor neuron prostaglandin E2 EP3 receptor isoform in a mouse model of amyotrophic lateral sclerosis. Biological &amp; Pharmaceutical Bulletin. 2015;38(12):1964&#x2013;1968. doi: 10.1248/bpb.b15-00418.</Citation><ArticleIdList><ArticleId IdType="doi">10.1248/bpb.b15-00418</ArticleId><ArticleId IdType="pubmed">26632188</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexianu M. E., Kozovska M., Appel S. H. Immune reactivity in a mouse model of familial ALS correlates with disease progression. Neurology. 2001;57(7):1282&#x2013;1289. doi: 10.1212/WNL.57.7.1282.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.57.7.1282</ArticleId><ArticleId IdType="pubmed">11591849</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai B. Y., Chen T. Y., Huang S. H., et al. Bidens pilosa formulation improves blood homeostasis and &#x3b2;-cell function in men: a pilot study. Evidence-Based Complementary and Alternative Medicine. 2015;2015:5. doi: 10.1155/2015/832314.832314</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/832314</ArticleId><ArticleId IdType="pmc">PMC4381681</ArticleId><ArticleId IdType="pubmed">25866541</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Y.-C., Yang M.-T., Lin C.-J., Chang C. L.-T., Yang W.-C. Bidens pilosa and its active compound inhibit adipogenesis and lipid accumulation via down-modulation of the C/EBP and PPAR&#x3b3; pathways. Scientific Reports. 2016;6(1) doi: 10.1038/srep24285.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep24285</ArticleId><ArticleId IdType="pmc">PMC4827119</ArticleId><ArticleId IdType="pubmed">27063434</ArticleId></ArticleIdList></Reference><Reference><Citation>Barber S. C., Higginbottom A., Mead R. J., Barber S., Shaw P. J. An in vitro screening cascade to identify neuroprotective antioxidants in ALS. Free Radical Biology &amp; Medicine. 2009;46(8):1127&#x2013;1138. doi: 10.1016/j.freeradbiomed.2009.01.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2009.01.019</ArticleId><ArticleId IdType="pmc">PMC2742740</ArticleId><ArticleId IdType="pubmed">19439221</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen D., Pan D., Tang S., et al. Administration of chlorogenic acid alleviates spinal cord injury via TLR4/NF&#x2011;&#x3ba;B and p38 signaling pathway anti&#x2011;inflammatory activity. Molecular Medicine Reports. 2018;17(1):1340&#x2013;1346. doi: 10.3892/mmr.2017.7987.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2017.7987</ArticleId><ArticleId IdType="pubmed">29115619</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultke E., Kendall E., Kamencic H., Ghong Z., Griebel R. W., Juurlink B. H. Quercetin promotes functional recovery following acute spinal cord injury. Journal of Neurotrauma. 2003;20(6):583&#x2013;591. doi: 10.1089/089771503767168500.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/089771503767168500</ArticleId><ArticleId IdType="pubmed">12906742</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J., Maoqiang L., Fan H., et al. Rutin attenuates neuroinflammation in spinal cord injury rats. The Journal of Surgical Research. 2016;203(2):331&#x2013;337. doi: 10.1016/j.jss.2016.02.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jss.2016.02.041</ArticleId><ArticleId IdType="pubmed">27363641</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller R. G., Bouchard J. P., Duquette P., et al. Clinical trials of riluzole in patients with ALS. Neurology. 1996;47(4, Supplement 2):86S&#x2013;92S. doi: 10.1212/WNL.47.4_Suppl_2.86S.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.47.4_Suppl_2.86S</ArticleId><ArticleId IdType="pubmed">8858057</ArticleId></ArticleIdList></Reference><Reference><Citation>Okada M., Yamashita S., Ueyama H., Ishizaki M., Maeda Y., Ando Y. Long-term effects of edaravone on survival of patients with amyotrophic lateral sclerosis. eNeurologicalSci. 2018;11:11&#x2013;14. doi: 10.1016/j.ensci.2018.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ensci.2018.05.001</ArticleId><ArticleId IdType="pmc">PMC6006910</ArticleId><ArticleId IdType="pubmed">29928711</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Signore S. J., Amante D. J., Kim J., et al. Combined riluzole and sodium phenylbutyrate therapy in transgenic amyotrophic lateral sclerosis mice. Amyotrophic Lateral Sclerosis. 2009;10(2):85&#x2013;94. doi: 10.1080/17482960802226148.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960802226148</ArticleId><ArticleId IdType="pubmed">18618304</ArticleId></ArticleIdList></Reference><Reference><Citation>Jablonski M. R., Markandaiah S. S., Jacob D., et al. Inhibiting drug efflux transporters improves efficacy of ALS therapeutics. Annals of Clinical Translational Neurology. 2014;1(12):996&#x2013;1005. doi: 10.1002/acn3.141.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.141</ArticleId><ArticleId IdType="pmc">PMC4284125</ArticleId><ArticleId IdType="pubmed">25574474</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoccolella S., Beghi E., Palagano G., et al. Riluzole and amyotrophic lateral sclerosis survival: a population-based study in Southern Italy. European Journal of Neurology. 2007;14(3):262&#x2013;268. doi: 10.1111/j.1468-1331.2006.01575.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2006.01575.x</ArticleId><ArticleId IdType="pubmed">17355545</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito H., Wate R., Zhang J., et al. Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice. Experimental Neurology. 2008;213(2):448&#x2013;455. doi: 10.1016/j.expneurol.2008.07.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2008.07.017</ArticleId><ArticleId IdType="pubmed">18718468</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang H. Y., Zhang J. J., Fu Z. F., et al. Therapeutic effects of hirsutella sinensis on the disease onset and progression of amyotrophic lateral sclerosis in SOD1G93A transgenic mouse model. CNS Neuroscience &amp; Therapeutics. 2019;26(1):90&#x2013;100. doi: 10.1111/cns.13182.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cns.13182</ArticleId><ArticleId IdType="pmc">PMC6930832</ArticleId><ArticleId IdType="pubmed">31318169</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Q., Wang Y., Zhang J., et al. Fingerprint analysis of Huolingshengji Formula and its neuroprotective effects in SOD1G93A mouse model of amyotrophic lateral sclerosis. Scientific Reports. 2018;8(1):p. 1668. doi: 10.1038/s41598-018-19923-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-19923-9</ArticleId><ArticleId IdType="pmc">PMC5786035</ArticleId><ArticleId IdType="pubmed">29374221</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall E. D., Oostveen J. A., Gurney M. E. Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia. 1998;23(3):249&#x2013;256. doi: 10.1002/(sici)1098-1136(199807)23:3&lt;249::aid-glia7&gt;3.0.co;2-#.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(sici)1098-1136(199807)23:3&lt;249::aid-glia7&gt;3.0.co;2-#</ArticleId><ArticleId IdType="pubmed">9633809</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawamata T., Akiyama H., Yamada T., McGeer P. L. Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. The American Journal of Pathology. 1992;140(3):691&#x2013;707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1886170</ArticleId><ArticleId IdType="pubmed">1347673</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardo A. C., Wong V., Benson L. M., et al. Loss of the astrocyte glutamate transporter GLT1 modifies disease in SOD1 (G93A) mice. Experimental Neurology. 2006;201(1):120&#x2013;130. doi: 10.1016/j.expneurol.2006.03.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2006.03.028</ArticleId><ArticleId IdType="pubmed">16753145</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchetto M. C. N., Muotri A. R., Mu Y., Smith A. M., Cezar G. G., Gage F. H. Non-cell-autonomous effect of human SOD1G37R astrocytes on motor neurons derived from human embryonic stem cells. Cell Stem Cell. 2008;3(6):649&#x2013;657. doi: 10.1016/j.stem.2008.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2008.10.001</ArticleId><ArticleId IdType="pubmed">19041781</ArticleId></ArticleIdList></Reference><Reference><Citation>Aebischer J., Cassina P., Otsmane B., et al. IFN&#x3b3; triggers a LIGHT-dependent selective death of motoneurons contributing to the non-cell-autonomous effects of mutant SOD1. Cell Death and Differentiation. 2011;18(5):754&#x2013;768. doi: 10.1038/cdd.2010.143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cdd.2010.143</ArticleId><ArticleId IdType="pmc">PMC3131923</ArticleId><ArticleId IdType="pubmed">21072055</ArticleId></ArticleIdList></Reference><Reference><Citation>Endo F., Komine O., Fujimori-Tonou N., et al. Astrocyte-derived TGF-&#x3b2;1 accelerates disease progression in ALS mice by interfering with the neuroprotective functions of microglia and T cells. Cell Reports. 2015;11(4):592&#x2013;604. doi: 10.1016/j.celrep.2015.03.053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2015.03.053</ArticleId><ArticleId IdType="pubmed">25892237</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Ambrosi N., Cozzolino M., Carr&#xec; M. T. Neuroinflammation in amyotrophic lateral sclerosis: role of redox (dys)regulation. Antioxidants &amp; Redox Signaling. 2018;29(1):15&#x2013;36. doi: 10.1089/ars.2017.7271.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2017.7271</ArticleId><ArticleId IdType="pubmed">28895473</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers D. R., Zhao W., Liao B., et al. Neuroinflammation modulates distinct regional and temporal clinical responses in ALS mice. Brain, Behavior, and Immunity. 2011;25(5):1025&#x2013;1035. doi: 10.1016/j.bbi.2010.12.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2010.12.008</ArticleId><ArticleId IdType="pmc">PMC3096756</ArticleId><ArticleId IdType="pubmed">21176785</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang C. L.-T., Kuo H.-K., Chang S.-L., et al. The distinct effects of a butanol fraction of Bidens pilosa plant extract on the development of Th1-mediated diabetes and Th2-mediated airway inflammation in mice. Journal of Biomedical Science. 2005;12(1):79&#x2013;89. doi: 10.1007/s11373-004-8172-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11373-004-8172-x</ArticleId><ArticleId IdType="pubmed">15864741</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>